Archived Information About the Funding Opportunity Announcement

Funding Opportunity Announcement (FOA) - active 6/28/19-8/30/19

Number: RFA-CA-19-031

Funding Opportunity Title: Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
Announcement Type: Reissue of RFA-CA-18-029 (see pre-application webinar information for RFA-CA-029, no longer active, below)
Companion Funding Opportunity: None
See: Frequently Asked Questions (FAQs)

Funding Opportunity Purpose

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet), for which the goals are as follows:

• Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials;
• Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.
• Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.